Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter
Paula Espinal1, Ignasi Roca, Jordi Vila
1Department of Microbiology, Hospital Clinic, School of Medicine, University of Barcelona, CRESIB, IDIBAPS, Spain.
Abstract:
Species of Acinetobacter other than Acinetobacter baumannii are involved in nosocomial infections. Acinetobacter lwoffii, Acinetobacter genomospecies 3 and Acinetobacter genomospecies 13TU are found in community- and nosocomial-acquired infections as well as in neonatal intensive care units. The non-baumannii Acinetobacter are normally highly susceptible to ciprofloxacin, ampicillin/sulbactam, gentamicin and tigecycline. Carbepenems show good activity although resistant isolates have been reported. Resistance to β-lactams other than carbapenems is associated with overexpression of chromosomal cephalosporinases and extended-spectrum β-lactamase acquisition, whereas resistance to carbapenems involves acquisition of carbapenemases. Quinolone resistance is related to gyrA and/or parC mutations but overexpresion of efflux proteins also plays an important role. With the development of novel and more accurate typing methodologies, an increase in infections caused by non-baumannii Acinetobacter might be observed in the future.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Effectiveness
Inhibitors of Bacterial Protein Synthesis

